 |
Photo = Yonhap news |
[Alpha Biz= Kim Jisun] Hanmi Science, the holding company of Hanmi Pharmaceutical Group, and its core business entity, Hanmi Pharmaceutical, held board meetings on Wednesday to finalize their board member candidates for approval at the upcoming annual general meeting (AGM) on March 26.
Hanmi Pharmaceutical Group aims to establish a solid "advanced governance system" through the newly formed board, where professional managers will handle operations while major shareholders support and oversee them.
Hanmi Science's board has nominated four internal director candidates: Lim Joo-hyun (Vice Chairman of Hanmi Science and Hanmi Pharmaceutical), Kim Jae-gyo (former Vice President of Meritz Securities), Shim Byung-hwa (former Executive Director of Samsung Biologics), and Kim Sung-hoon (former Executive Director of Hanmi Science). Additionally, three external director candidates were selected: Choi Hyun-man (former CEO of Mirae Asset Securities), Kim Young-hoon (former judge at the Seoul High Court), and Shin Yong-sam (professor at Seoul St. Mary's Hospital, Catholic University of Korea).
Among them, Kim Jae-gyo has been appointed as the new CEO and recently joined Hanmi Science as Vice Chairman. Shim Byung-hwa has been named CFO and joined as Vice President.
Meanwhile, Hanmi Pharmaceutical’s board nominated Choi In-young (Head of Hanmi Pharmaceutical R&D Center) as an internal director, Kim Jae-gyo as an other non-executive director, and Lee Young-goo (Managing Partner at Daeryuk & Aju Law Firm) as an external director. These appointments will be presented for approval at the AGM.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
